Pharmaceuticals company Sudeep Pharma announced Q1FY27 results Consolidated Financial Highlights: Revenue from Operations: For Q1FY27, revenue reached Rs 15,827.05 lakh, representing a growth of 26.70% YoY compared to Rs 12,491.75 lakh in Q1FY26, while declining by 13.20% QoQ from Rs 18,233.87 lakh in Q4FY26. Total Income: The total income for the quarter stood at Rs 16,371.59 lakh, up 25.86% YoY from Rs 13,007.60 lakh in Q1FY26 and down 13.27% QoQ from Rs 18,876.34 lakh in Q4FY26. Profit After Tax (PAT): PAT for Q1FY27 was Rs 4,058.69 lakh, showing a YoY increase of 29.80% from Rs 3,126.92 lakh in Q1FY26 and a QoQ decrease of 16.38% from Rs 4,853.82 lakh in Q4FY26. Full Year Performance: For the full year FY26, the group reported Revenue from operations of Rs 64,225.80 lakh and PAT of Rs 17,428.47 lakh. Standalone Financial Highlights: Revenue from Operations: Standalone revenue for Q1FY27 was Rs 10,568.33 lakh, an increase of 31.82% YoY from Rs 8,017.42 lakh in Q1FY26 and a growth of 31.83% QoQ from Rs 8,016.71 lakh in Q4FY26. Total Income: Total income for the quarter stood at Rs 11,508.36 lakh, a growth of 32.59% YoY from Rs 8,679.38 lakh in Q1FY26 and a 28.17% QoQ increase from Rs 8,978.62 lakh in Q4FY26. Profit After Tax (PAT): Standalone PAT for Q1FY27 reached Rs 3,382.85 lakh, growing 34.21% YoY from Rs 2,520.49 lakh in Q1FY26 and up 31.29% QoQ from Rs 2,576.56 lakh in Q4FY26. Full Year Performance: For the full year FY26, standalone Revenue from operations was Rs 33,850.54 lakh and PAT was Rs 10,758.07 lakh. Business Highlights: Pharmaceutical, food and nutrition segment: This segment generated revenue of Rs 10,841.37 lakh in Q1FY27, representing a growth of 30.64% YoY. The segment result (before finance costs and tax) improved significantly to Rs 4,002.45 lakh from Rs 2,657.21 lakh in Q1FY26. Speciality ingredients segment: Revenue for this segment reached Rs 4,985.68 lakh in Q1FY27, an 18.90% YoY increase. However, the segment result (before finance costs and tax) decreased to Rs 1,088.60 lakh compared to Rs 1,405.07 lakh in Q1FY26. Strategic Acquisitions: The Group completed the final purchase price allocation (PPA) for the acquisition of an 85% equity interest in Nutrition Supplier & Services (Ireland) Limited (NSS). NSS was acquired for a purchase price of Rs 12,857.63 lakh in April 2025 and is now a step-down subsidiary. IPO Proceeds: Following the listing on the NSE and BSE on November 28, 2025, the company received net proceeds of Rs 8,833.59 lakh. Utilization of Funds: As of June 30, 2026, the company utilized a total of Rs 1,287.96 lakh from the IPO proceeds. This includes Rs 35.77 lakh for capital expenditure towards procurement of machinery for the Nandesari Facility I and Rs 1,252.19 lakh for general corporate purposes. The unutilized balance of Rs 7,545.63 lakh is currently held as bank term deposits. Result PDF